Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | PHASE2 | COMPLETED | 25 | — | — | Jul 1, 1999 | - | Apr 6, 2017 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Study treatment arm with G-CSF |
| Name | Type | Description |
|---|---|---|
| Cyclophosphamide | DRUG | preparative cytoreduction |
| fludarabine | DRUG | preparative cytoreduction |
| cyclosporine | DRUG | immunosuppressive therapy |
| methotrexate | DRUG | immunosuppressive therapy |
| G-CSF | BIOLOGICAL | foster engraftment |
Inclusion Criteria - Patient: * AML, ALL,CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL, MDS, RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA, Aplastic Anemia, Multiple Myeloma, MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET * Age less than 65 years * Patients must have a healthy family mem...